Literature DB >> 29626124

In Vivo Characterization of 4 68Ga-Labeled Multimeric RGD Peptides to Image αvβ3 Integrin Expression in 2 Human Tumor Xenograft Mouse Models.

Daphne Lobeek1, Gerben M Franssen2, Michelle T Ma3, Hans-Jürgen Wester4, Clemens Decristoforo5, Wim J G Oyen2,6, Otto C Boerman2, Samantha Y A Terry3, Mark Rijpkema2.   

Abstract

αvβ3 integrins play an important role in angiogenesis and cell migration in cancer and are highly expressed on the activated endothelial cells of newly formed blood vessels. Here, we compare the targeting characteristics of 4 68Ga-labeled multimeric cyclic arginine-glycine-aspartate (RGD)-based tracers in an αvβ3 integrin-expressing tumor model and a tumor model in which αvβ3 integrin is expressed solely on the neovasculature.
Methods: Female BALB/c nude mice were subcutaneously injected with SK-RC-52 (αvβ3 integrin-positive) or FaDu (αvβ3 integrin-negative) tumor cells. 68Ga-labeled DOTA-(RGD)2, TRAP-(RGD)3, FSC-(RGD)3, or THP-(RGD)3 was intravenously administered to the mice (0.5 nmol per mouse, 10-20 MBq), followed by small-animal PET/CT imaging and ex vivo biodistribution studies 1 h after injection. Nonspecific uptake of the tracers in both models was determined by coinjecting an excess of unlabeled DOTA-(RGD)2 (50 nmol) along with the radiolabeled tracers.
Results: Imaging and biodistribution data showed specific uptake in the tumors for each tracer in both models. Tumor uptake of 68Ga-FSC-(RGD)3 was significantly higher than that of 68Ga-DOTA-(RGD)2, 68Ga-TRAP-(RGD)3, or 68Ga-THP-(RGD)3 in the SK-RC-52 model but not in the FaDu model, in which 68Ga-FSC-(RGD)3 showed significantly higher tumor uptake than 68Ga-TRAP-(RGD)3 Most importantly, differences were also observed in normal tissues and in tumor-to-blood ratios.
Conclusion: All tracers showed sufficient targeting of αvβ3 integrin expression to allow for tumor detection. Although the highest tumor uptake was found for 68Ga-FSC-(RGD)3 and 68Ga-THP-(RGD)3 in the SK-RC-52 and FaDu models, respectively, selection of the optimal tracer for specific diagnostic applications also depends on tumor-to-blood ratio and uptake in normal tissues; these factors should therefore also be considered.
© 2018 by the Society of Nuclear Medicine and Molecular Imaging.

Entities:  

Keywords:  68Ga; RGD peptides; angiogenesis; multimers; αvβ3 integrin

Mesh:

Substances:

Year:  2018        PMID: 29626124      PMCID: PMC6175042          DOI: 10.2967/jnumed.117.206979

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  31 in total

Review 1.  Role of integrins in cell invasion and migration.

Authors:  John D Hood; David A Cheresh
Journal:  Nat Rev Cancer       Date:  2002-02       Impact factor: 60.716

2.  microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide.

Authors:  Yun Wu; Xianzhong Zhang; Zhengming Xiong; Zhen Cheng; Darrell R Fisher; Shuang Liu; Sanjiv S Gambhir; Xiaoyuan Chen
Journal:  J Nucl Med       Date:  2005-10       Impact factor: 10.057

Review 3.  RGD-mediated delivery of small-molecule drugs.

Authors:  Sotirios Katsamakas; Theodora Chatzisideri; Savvas Thysiadis; Vasiliki Sarli
Journal:  Future Med Chem       Date:  2017-04-10       Impact factor: 3.808

4.  Be spoilt for choice with radiolabelled RGD peptides: preclinical evaluation of ⁶⁸Ga-TRAP(RGD)₃.

Authors:  Johannes Notni; Karolin Pohle; Hans-Jürgen Wester
Journal:  Nucl Med Biol       Date:  2012-09-18       Impact factor: 2.408

5.  RGD-K5 PET/CT in patients with advanced head and neck cancer treated with concurrent chemoradiotherapy: Results from a pilot study.

Authors:  Shih-Hsin Chen; Hung-Ming Wang; Chien-Yu Lin; Joseph Tung-Chieh Chang; Chia-Hsun Hsieh; Chun-Ta Liao; Chung-Jan Kang; Lan-Yan Yang; Tzu-Chen Yen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-02-27       Impact factor: 9.236

6.  Can 111In-RGD2 monitor response to therapy in head and neck tumor xenografts?

Authors:  Samantha Y A Terry; Keelara Abiraj; Jasper Lok; Danny Gerrits; Gerben M Franssen; Wim J G Oyen; Otto C Boerman
Journal:  J Nucl Med       Date:  2014-10-27       Impact factor: 10.057

Review 7.  αvβ3 Integrin-Targeted Peptide/Peptidomimetic-Drug Conjugates: In-Depth Analysis of the Linker Technology.

Authors:  Alberto Dal Corso; Luca Pignataro; Laura Belvisi; Cesare Gennari
Journal:  Curr Top Med Chem       Date:  2016       Impact factor: 3.295

8.  Improved targeting of the alpha(v)beta (3) integrin by multimerisation of RGD peptides.

Authors:  Ingrid Dijkgraaf; John A W Kruijtzer; Shuang Liu; Annemieke C Soede; Wim J G Oyen; Frans H M Corstens; Rob M J Liskamp; Otto C Boerman
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-08-15       Impact factor: 9.236

9.  Two ⁹⁰Y-labeled multimeric RGD peptides RGD4 and 3PRGD2 for integrin targeted radionuclide therapy.

Authors:  Zhaofei Liu; Jiyun Shi; Bing Jia; Zilin Yu; Yan Liu; Huiyun Zhao; Fang Li; Jie Tian; Xiaoyuan Chen; Shuang Liu; Fan Wang
Journal:  Mol Pharm       Date:  2011-02-15       Impact factor: 4.939

10.  Enhancing PET Signal at Target Tissue in Vivo: Dendritic and Multimeric Tris(hydroxypyridinone) Conjugates for Molecular Imaging of αvβ3 Integrin Expression with Gallium-68.

Authors:  Cinzia Imberti; Samantha Y A Terry; Carleen Cullinane; Fiona Clarke; Georgina H Cornish; Nisha K Ramakrishnan; Peter Roselt; Andrew P Cope; Rodney J Hicks; Philip J Blower; Michelle T Ma
Journal:  Bioconjug Chem       Date:  2016-12-14       Impact factor: 4.774

View more
  7 in total

1.  68Ga-DOTA-E[c(RGDfK)]2 PET Imaging of SHARPIN-Regulated Integrin Activity in Mice.

Authors:  Riikka Siitonen; Emilia Peuhu; Anu Autio; Heidi Liljenbäck; Elina Mattila; Olli Metsälä; Meeri Käkelä; Tiina Saanijoki; Ingrid Dijkgraaf; Sirpa Jalkanen; Johanna Ivaska; Anne Roivainen
Journal:  J Nucl Med       Date:  2019-03-08       Impact factor: 10.057

2.  99mTc-labeled peptide targeting interleukin 13 receptor α 2 for tumor imaging in a cervical cancer mouse model.

Authors:  Yujing Du; Zhao Chen; Xiaojiang Duan; Ping Yan; Chunli Zhang; Lei Kang; Rongfu Wang
Journal:  Ann Nucl Med       Date:  2022-01-15       Impact factor: 2.668

3.  The effects of trace metal impurities on Ga-68-radiolabelling with a tris(3-hydroxy-1,6-dimethylpyridin-4-one) (THP) chelator.

Authors:  Ruslan Cusnir; Andrew Cakebread; Margaret S Cooper; Jennifer D Young; Philip J Blower; Michelle T Ma
Journal:  RSC Adv       Date:  2019-11-14       Impact factor: 4.036

4.  A Clinical Feasibility Study to Image Angiogenesis in Patients with Arteriovenous Malformations Using 68Ga-RGD PET/CT.

Authors:  Daphne Lobeek; Frédérique C M Bouwman; Erik H J G Aarntzen; Janneke D M Molkenboer-Kuenen; Uta E Flucke; Ha-Long Nguyen; Miikka Vikkula; Laurence M Boon; Willemijn Klein; Peter Laverman; Wim J G Oyen; Otto C Boerman; Samantha Y A Terry; Leo J Schultze Kool; Mark Rijpkema
Journal:  J Nucl Med       Date:  2019-09-13       Impact factor: 10.057

5.  Tuning the properties of tris(hydroxypyridinone) ligands: efficient 68Ga chelators for PET imaging.

Authors:  Cinzia Imberti; Yu-Lin Chen; Calum A Foley; Michelle T Ma; Brett M Paterson; Yifu Wang; Jennifer D Young; Robert C Hider; Philip J Blower
Journal:  Dalton Trans       Date:  2019-03-26       Impact factor: 4.390

6.  Imaging angiogenesis in patients with head and neck squamous cell carcinomas by [68Ga]Ga-DOTA-E-[c(RGDfK)]2 PET/CT.

Authors:  D Lobeek; M Rijpkema; S Y A Terry; J D M Molkenboer-Kuenen; L Joosten; E A J van Genugten; A C H van Engen-van Grunsven; J H A M Kaanders; S A H Pegge; O C Boerman; W L J Weijs; M A W Merkx; C M L van Herpen; R P Takes; E H J G Aarntzen; W J G Oyen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-03-20       Impact factor: 9.236

Review 7.  Imaging of peripheral vascular malformations - current concepts and future perspectives.

Authors:  Vanessa F Schmidt; Max Masthoff; Michael Czihal; Beatrix Cucuruz; Beate Häberle; Richard Brill; Walter A Wohlgemuth; Moritz Wildgruber
Journal:  Mol Cell Pediatr       Date:  2021-12-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.